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1. Introduction 
Cancer biology has focused for years on better characterizing what makes cancer distinctive 
relative to normal tissue so as to better define targets for treatment. This has resulted in our 
current cancer paradigm in which cancers arise through an essentially cell autonomous 
series of variable cellular genetic and epigenetic events that drives the malignant process 1, 2. 
The corollary of this model is that cancer is a highly complex process with no two individual 
cancers being identical leading in turn to the current trend towards “personalizing” therapy. 
We propose that there is a much simpler way to view cancer, one in which it is viewed from 
a tissue rather than a cellular perspective. From this vantage point, properties are 
“distributed” among cell populations, creating a highly integrated cell population and that 
treatment is better aimed at perturbing the system as a whole rather than a particular gene 
or receptor target. This physiological approach thus focuses on two universal attributes of 
malignancy that have not yet been linked experimentally: (i) the need for growing tumors to 
establish an adequate blood supply, i.e., neoangiogenesis 3, 4; and (ii) the unique metabolism 
of tumor tissue in which an inordinate amount of energy is derived through glycolysis 
(GLY) rather than oxidative phosphorylation (OXPHOS) even in the presence of adequate 
oxygen (aerobic glycolysis) 5, 6. Although much research has focused on these two topics, the 
impact they have upon each other has not been addressed to any extent in living organisms, 
despite there being substantial information on the relationship between flow and 
metabolism in normal tissues. Admittedly, one major reason for this lack of study has been 
technical, i.e., although flow can be assessed, there has not until recently been a way to 
assess tumor metabolism in intact animals in real time.  
The recent introduction of the anti-VEGF monoclonal antibody bevacizumab into the field of 
brain tumor therapeutics has resulted in an unprecedented rapid improvement in MRI 
abnormalities and mass effect which led to its fast track approval by the FDA in 2009 based 
on Phase II studies 7, 8. While dramatic, this response is transient and associated with late 
failures that are largely resistant to salvage therapies (Figure 1). This phenomenon has been 
recently labeled a “pseudoresponse” 9, 10 and has generated a second wave of studies that 
have been much less optimistic about the prospects of this therapy 11.  
In this review, we will develop the argument that when viewed from the tissue perspective, 
the pseudoresponse reflects the effect of blood flow changes that result in a depletion of 
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nutrients, especially glucose and lactate, that results in increased tissue OXPHOS to 
maintain energy needs. This results in a “starvation” state within the cancer tissue that 
temporarily opens a therapeutic window that closes as the tumor tissue adapts to this crisis. 
We term this the “Warburg-Folkman” effect and postulate that its magnitude will be 
proportional to the real time lactate/bicarbonate level observed within tumor tissue after 
anti-angiogenic therapy that can now be visualized in the intact organism with the recent 
refinement in 13C1-pyruvate MRS technologies.  
 
 
Fig. 1. Demonstration of response to bevacizumab in recurrent glioblastoma. Top two panels 
reflect an axial T1 enhanced and axial FLAIR image from a 43 year old woman with 
recurrent GBM before first infusion of BEV while the bottom two panels represent imaging 
performed after third infusion. Note the marked improvement in enhancement and amount 
of mass effect after treatment. However, there is now an increased area of T2 FLAIR 
abnormality distant from original site of relapse (Arrow). This represents new infiltrative 
tumor. 
2. Neoangiogenesis in GBM 
Four decades ago, Folkman proposed that all solid tumors are dependent on the formation 
of new blood vessels (angiogenesis) based on the observation that experimental solid 
tumors otherwise entered a dormant state or died once their size reached 2-3 mm 4. In this 
and subsequent papers (for a review of this work, consult 12-14), he noted a strong interaction 
and counterdependency between endothelium and tumor cells that suggested the presence 
of a diffusible messenger released from tumor cells was transitioning endothelial cells from 
a resting state to one capable of forming new capillaries.  
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Though his hypothesis was initially met with a high level of skepticism, subsequent studies 
confirmed the relationship between neoangiogenesis and cancer progression as well as 
characterizing several cytokines that were important in mediating these effects. Numerous 
pro- and anti-angiogenic mediators are now known that respond to adverse conditions such 
as hypoxia so that the balance is tipped in favor of angiogenesis ( i.e., the “angiogenic 
switch”). Although a number of these factors have been identified including bFGF and 
members of the EGF receptor family 15, 16, the most prominent factor mediating angiogenesis 
is the family of vascular endothelial growth factor (VEGF) molecules. The VEGF family 
consists of the VEGF ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, platelet derived growth 
factor (PDGF) and placental growth factor. These ligands bind to the VEGF receptor 
(VEGFR) tyrosine kinases VEGFR-1 and VEGFR-2. The most important of these ligands is 
VEGF-A which by primarily binding to VEGFR-2 regulates endothelial cell survival, 
proliferation, vascular permeability and migration. In hypoxic conditions, VEGF-A is 
primarily induced via hypoxic inducible factor (HIF-1┙), which in the presence of a hypoxic 
environment is dissociated from the Von Hippel Lindau protein allowing it to bind to 
promoter regions of several pro-angiogenic factors including VEGF 17. 
Among cancers, glioblastoma (GBM) is among the most highly vascularized, the extent of 
which correlates closely with tumor proliferation and aggressiveness 18. Vascularization 
occurs via three mechanisms: arteriogenesis (utilizing collaterals from a pre-existing blood 
supply to augment metabolic demands), vasculogenesis (formation of new vessels via the 
migration and differentiation of progenitor cells into endothelial cells) and angiogenesis (the 
production of new blood vessels from pre-existing ones). When the angiogenic cascade is 
triggered in GBMs, a wide range of cells can become tumor endothelial cells, including 
circulating progenitor cells that are mobilized from the bone marrow and other tissues as 
well as other hematopoietic cells and even glioma cells themselves 19-23.  
While it is not clear how much tumor vascularization is due to co-option of other vessels 
relative to the creation of new ones, it is widely accepted that angiogenesis is a key factor in 
tumor proliferation. Neoangiogeneic vessels are tortuous, leaky, and dilated with aberrant 
interconnections and abnormal basement membranes resulting in inefficient and 
heterogeneous blood flow as well as increased blood volume within the tumor 24. The 
endothelial cells lining these vessels are abnormal with loosely attached or absent pericytes 
and basement membranes are often absent or abnormally thickened.  
3. Anti-VEGF therapy and the pseudoresponse 
The discovery that cancer angiogenesis is dependent on cytokines released by tumor cells 
spurred interest in developing agents that could interrupt these cytokine loops so as to 
impact tumor growth via inhibiting vessel formation. After VEGF’s identification as perhaps 
the most important mediator of this process (including one of the seminal papers describing 
its high concentration in GBM 25), a number of strategies were designed to block VEGF’s 
contribution to this process. This led to the development of bevacizumab, the first anti-
angiogenic agent to be approved and be widely used.  
Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds with 
high affinity to VEGF ligand preventing its interaction with the VEGF-1 and VEGF-2 
receptor on the surface of endothelial cells, thus preventing VEGF induced endothelial cell 
migration, proliferation and vascular permeability 26. Bevacizumab (and other anti-VEGF 
therapies) exerts its effects via multiple mechanisms that block the development of new 
www.intechopen.com
 
Brain Tumors - Current and Emerging Therapeutic Strategies 
 
56
aberrant vessels and induce regression of existing aberrant vasculature, thus resulting in 
tumor growth arrest. This so-called “normalization” of mature vasculature at least 
theoretically also results in improved susceptibility to treatment via improved delivery of 
chemotherapeutic agents and via radiosensitization from improved oxygen delivery 24.  
Bevacizumab was approved in 2004 for first line use in people with metastatic colon cancer 
but despite the observation that GBMs were associated with the highest VEGF levels among 
cancers, its use was delayed in brain tumor patients because of the fear of increasing 
hemorrhagic risk. The dramatic, immediate effect of bevacizumab on MRI enhancement and 
clinical status noted when it was finally utilized 27, 28 generated an unprecedented initial 
enthusiasm that led to a fast-track FDA approval for recurrent glioma based on two pivotal 
Phase II studies 7, 8. 
Unfortunately, and perhaps not unexpectedly, despite the impressive radiologic responses 
with corresponding clinical benefit seen early after BEV treatment, these results were not 
sustained over long intervals, resulting in only a modest overall survival benefit. What was 
especially disappointing was the observation of an increased glioma invasiveness that often 
resulted in the development of a gliomatosis picture 29. This disappointing outcome has 
tempered enthusiasm concerning the overall role of BEV in GBM therapies and led to 
intensive research aimed at understanding why this failure occurs. Among the mechanisms 
invoked for this observation is an up regulation of alternative pro-angiogenic factors such as 
the pro-angiogenic fibroblast growth factor 30, increased protection of tumor vasculature by 
increasing pericyte coverage, recruitment of pro-angiogenic inflammatory cells and a 
cooption of normal vessels by the invading tumor cells 31. At the root of most of the 
explanation for why anti-VEGF therapy is ultimately ineffective is that, by diminishing flow, 
intratumoral hypoxia is increased, inducing tumor cells to become more aggressive and 
invasive 32-34. 
While the clinical observation of a worsening MRI occurring as a result of treatment effect 
rather than tumor progression has been well characterized (i.e., pseudoprogression 35), the 
introduction of anti-angiogenic therapies such as BEV produced a diametrically opposite 
effect of rapid resolution of MRI abnormalities that, despite its magnitude, is as much of a 
function of blocking VEGF’s effect on permeability as it is on a cytotoxic response. This 
phenomenon has therefore been labeled a “pseudoresponse” 9, in part to reflect the 
impression that it is similar to what is occasionally seen when steroids are administered to 
brain tumor patients and is supported by several observations including its association with 
increased invasive nonenhancing tumor seen on T2/FLAIR imaging representing dispersion 
of the tumor in an infiltrating pattern 10 and the demonstration of a rapid radiologic 
response, rebound enhancement on discontinuation and rapid re-response on 
recontinuation with anti-VEGF therapy 33, 36, 37.  
Within the framework of neoangiogenesis, the pseudoresponse is felt to be a manifestation 
of an initial “normalization” of perfusion that increases hypoxia, both increasing apoptosis 
initially as well as upregulating the HIF1 axis. It is through this latter activation that cancer 
cells initiate cellular programs that increase invasiveness and ultimately lead to a more 
resistant tumor 38. Such observations have cast a pall over the early excitement generated by 
the introduction of BEV and have led many workers to question its ultimate value in GBM 
treatment 11, 32.  
While it is certainly valid and reasonable to assess the effects of anti-VEGF therapies in 
terms of hypoxia, it should be noted that a growing tumor is already adapted to a very low 
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oxygen tension. It is therefore unclear why any change in oxygen delivery should have such 
a profound impact. We believe that this concept is misleading and unproven and offer a 
fundamentally more logical explanation that relates to the cancer’s peculiar metabolism, 
which we next address. 
4. Cancer’s peculiar metabolism 
The drive to acquire cell mass and proliferate requires an adequate energy supply and 
building blocks, underscoring the need for ample amounts of energy in the form of ATP. 
There are two general ways in which this can be accomplished. Oxidative phosphorylation 
(OXPHOS), which takes place in the mitochondria, is an oxygen-dependent process in 
which pyruvate (which can be derived from a number of sources, especially glucose) is 
converted to acetyl-CoA which is then oxidized to CO2 and H2O producing NADH. NADH 
is further oxidized via the electron transport chain using oxygen as the final electron 
acceptor, ultimately generating a net of 36 ATP/glucose molecule. Alternatively, cells may 
use glycolysis (GLY), in which glucose is converted to pyruvate, generating 2 ATP/glucose 
molecule, completely bypassing the mitochondria. In normal cells, the balance between 
these two pathways is highly oxygen dependent; in the presence of adequate amounts of 
oxygen, cells utilize the more efficient OXPHOS while when oxygen is inadequate, the cell 
transitions to the less efficient GLY (Pasteur Effect) 39. 
Under optimal conditions, cells derive ninety percent of their energy from OXPHOS and ten 
percent from GLY. Over 80 years ago, Otto Warburg observed that tumor cells generate an 
inordinate amount of ATP via GLY, even in the presence of adequate oxygen levels (aerobic 
glycolysis) 5, 6, 40. This preferential shift to the glycolytic pathway is not absolute, instead 
representing a shift from a baseline glycolytic rate of 10% seen in normal cells to over fifty 
percent41 (Figure 2). In association with this shift towards GLY, tumors rely almost 
exclusively on glucose relative to other substrates (such as fatty acids) for energy needs.  
Although it remains unexplained why tumors overutilize GLY, its universal presence that 
persists even under normal oxygenation and its close correlation with tumor aggressiveness 
suggests a survival and growth benefit that exceeds the apparent inefficiency of the 
glycolytic pathway 39. Despite its persistence under normal oxygen levels, several studies 
still point to an important role of hypoxia in this process, perhaps because the byproducts of 
GLY lead to acidification of the micro-environment. An acidic environment is toxic to 
adjacent normal cells, assists in destruction of extracellular matrix and triggers angiogenesis, 
suggesting that the glycolytic shift is necessary for evolution into invasive cancer 39, 42. 
Moreover, as tumor cells proliferate they physically increase their distance from their 
vascular supply creating additional areas of low oxygen tension that results in activation of 
HIF1, which in turn upregulates genes that code for proteins important in cancer 
development and proliferation including glucose metabolism, apoptosis resistance, 
invasion, angiogenesis and metastasis 43.  
As tumors become vascularized, the glycolytic phenotype persists despite improved 
oxygenation. Although the reasons for this remain unclear, one potential explanation relates 
to the fact that while aerobic glycolysis is much less efficient than oxidative respiration, its 
kinetics are such that in the presence of excess substrate, it may result in more ATP 
production as a function of time than can be obtained with OXPHOS 43, 44. Vasquez et al. 
studied a model of ATP flux demonstrating that glucose uptake capacity and solvent 
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capacity of the cytoplasm are important factors. They proposed that at lower levels of 
glucose uptake OXPHOS is most efficient but once a threshold has been reached, a gradual 
decrease in OXPHOS relative to GLY results in more efficient ATP production 44. 
Alternatively, the reasons underlying the persistent dependence on GLY may be related to 
the fact that rapidly dividing cells become dependent on this pathway for production of 
nutrients such as amino acids, nucleotides and lipids needed for development of new cells 
at a sufficient rate for a rapidly dividing tumor 45. 
 
 
Fig. 2. Simplified graphic that demonstrates some key features of Warburg effect. Under 
normal conditions, approximately 90% of glucose and other energy substrates are efficiently 
metabolized via the mitochondria. Only 10% of glucose is metabolized via glycolysis to 
lactate. In solid cancers, however, there is a shift towards increased glycolysis and now over 
50% of ATP is generated through glycolysis. In association with this, the tumor environment 
is characterized by increased blood volume, stasis and low O2 tension and pH. For more 
detailed recent descriptions of tumor metabolism, the reader is referred to 39, 42, 46, 60. 
Although Warburg proposed that the glycolytic shift related to defective mitochondria, this 
has proven to be an oversimplification in that this organelle definitely functions in cancer 
cells, albeit not always at a normal level46. In fact, since GLY is a characteristic of normal 
rapidly proliferating tissues, this shift can occur even in the presence of normally 
functioning mitochondria 45. Instead, it is more likely that this shift results from a number of 
cytokines and oncogenic mutations that combine to effect increased GLY. For instance, HIF1 
increases GLY and down regulates mitochondrial function by activating genes involved in 
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glucose uptake such as GLUT1 as well as enzymes responsible for the glycolytic breakdown 
of glucose such as phosphofructokinase, aldolase and pyruvate dehydrogenase 41. Mutations 
that either inactivate p53 or activate NF-k┚ can also result in a shift towards producing 
energy via GLY as do environmental triggers such as acidosis and increased extracellular 
lactate 47.  
5. Linking blood flow with metabolism to explain the BEV pseudoresponse 
In the modern era, cancer is viewed as essentially a cell autonomous phenomenon. In this 
context, the Warburg effect has therefore been addressed primarily through attempting to 
ascertain what genetic mutations underlie the shift towards GLY. This has also led many to 
question its universality for all cancers since it is well documented that at least some cancer 
cells definitely harness energy via OXPHOS.  
In our view, however, the Warburg effect is a tissue not a cell phenomenon, meant to 
connote the net activity of GLY vs. OXPHOS in the tissue, not the cell. This is in keeping 
with Warburg’s original descriptions of the process in which he utilized animal preparations 
to demonstrate the effect 6. In fact, within the tumor itself, it would be advantageous from 
the point of view of distributing energy substrates if certain cells used GLY to increase 
extracellular lactate concentrations that can then be used by other cells for OXPHOS (similar 
to the astrocyte/neuron relationship 48; interestingly, a similar distribution of function has 
been proposed for breast cancers 49). In steady state, therefore, within cancers including 
those of the brain, this environment is associated with increased blood volume, increased 
lactate and decreased blood flow, which results in a substrate “excess”, which as is 
predicted by models that examine energy utilization within tissues, favors GLY 44.  
Such a steady state requires an adequate amount of blood flow to deliver adequate amounts 
of glucose to support the process, as well as a high amount of stasis to keep lactate available. 
It follows therefore that in addition to supporting adequate blood vessel formation to 
support the growing tumor, VEGF should also be crucial to supporting the cancer’s 
metabolism. We propose therefore that it is this linkage between VEGF, blood vessel 
maintenance and tumor metabolism that explains the profound initial effects of BEV on 
GBM and suggest it be named the Warburg-Folkman effect to honor the two scientists 
whose concepts provide its foundation. We propose that the paring of the tumor vasculature 
(or “normalization”) after BEV results in a period of acute tumor “starvation” resulting from 
lowered glucose (delivery of which is decreased due to vascular constriction lowering flow) 
and lactate (removal of which is increased due to decreased stasis) levels (Figure 3). This 
creates a situation wherein cells within the cancer must resort to the more efficient OXPHOS 
in the presence of decreased substrate. This forced utilization of mitochondria results in the 
exposure of cells to pro-apoptotic factors such as cytochrome C and apoptosis inducing 
factor and increases reactive oxygen species, increasing susceptibility of these cells to 
apoptosis 4550.  
In effect, therefore, we believe the observed clinical pseudoresponse represents an acute 
crisis for the cancer tissue, which responds over time by adaptations that favor “dispersion”, 
a term we prefer to invasion since we believe this represents a compensatory process in 
which tumor cells migrate to areas where the supply of energetic substrates is more 
favorable rather than an evolution to a more aggressive tumor. Such a model would suggest 
that while the effect may be transient, the acute removal of VEGF creates a period in which 
tumors should be extremely vulnerable to further metabolic perturbations, perhaps to the 
point where they can be induced to “collapse”.  
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Fig. 3. Proposed early effect of VEGF blockage on the tumor environment: the Warburg-
Folkman effect. The effect of removing VEGF is to cause a vessel “paring” that has been 
proposed to “normalize” flow. We propose that this has the effect of acutely depleting 
energy substrates—both glucose and lactate—through decreased delivery and increased 
removal, respectively. This results in increase mitochondrial utilization that results in 
increased OXPHOS as well as increased ROS production.  
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6. Measuring OXPHOS and GLY in intact organisms; MRS of hyperpolarized 
13
C1-pyruvate  
Since our proposal predicts a change in tumor metabolism at the tissue level with the 
introduction of anti-VEGF therapy, its proof depends on a tool in which the relative 
amounts of GLY and OXPHOS can be ascertained in the living organism. Until recently, 
therefore, this question could not easily be addressed. On first glance, one could consider 
using FDG PET scanning, the importance of which in cancer diagnostics is derived from 
Warburg’s observations and is dependent upon the upregulation of glucose uptake 
mechanisms in neoplasms compared to normal surrounding tissue. FdG is an analogue of 
glucose and areas of increased FDG uptake indicate increased tissue metabolic activity and 
the amount of uptake correlates with tumor aggressiveness 51. However, while FDG PET 
scanning also indirectly reflects the Warburg effect (because cancers must up regulate 
glucose transporters to maintain their metabolism), it does not provide a real time picture of 
the cancer’s metabolism and does not measure either OXPHOS or GLY. A similar problem 
exists with conventional MRI techniques; thus, one can measure total lactate using proton 
MRS, but this only reflects the total pool, not the throughput. 
 
 
Fig. 4. (A) Single acquisition in vivo 13C spectrum from a rat heart following the injection of 
hyperpolarized 13C1-Pyr. 13C-Pyr and its products 13C-Lac, 13C-Ala, and 13C-BiC are easily 
visualized. A small fraction of the 13C-Pyr is in equilibrium with metabolically inactive 13C-
Pyr-hydrate. (B) (left) H&E stained cross-section of rat brain with implanted glioma. (right) 
Dynamic 13C metabolic imaging results: TR = 3 s, 2.7x2.7x5 mm3 nominal voxels. ROIs 
selected for further analysis are shown on the proton images. Elevated lactate is clearly 
visualized within the tumor. 
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A novel technology has being developed that can address these important questions, 
however. In vivo hyperpolarized 13C MRS achieves dramatically enhanced signal to noise 
ratios, thus enabling the real-time investigation of metabolism with more than 10,000-fold 
signal increase over conventional 13C methods 52. It provides unprecedented opportunities 
for real-time imaging of in vivo metabolic pathways critical to the identification and 
evaluation of cancer 53-57. In terms of studying the Warburg-Folkman effect, it enables the 
quantitative assessment of the fate of labeled pyruvate, a key nodal point in the metabolic 
pathway in which glucose is either converted to lactate (which reflects GLY) or acetyl CoA 
(which then enters the Krebs cycle, resulting in bicarbonate production, which reflects 
OXPHOS) (Figure 4). With this technology, the amount of lactate and bicarbonate produced 
during a 60-90 second period after a labeled injection of pyruvate can be measured, thus 
permitting generation of a lactate/HCO3- ratio (the Glycolytic Index). Two published studies 
have already demonstrated increased lactate production in brain cancers this way 58, 59, and 
this technology is already being tested in the clinic.  
This technology therefore offers the prospect of being able to obtain a metabolic “snapshot” 
at multiple times during the course of cancer and offers an ideal way to assess the BEV’s 
impact on glioma metabolism. Our prediction is that the Glycolytic Index produced after a 
pyruvate probe will be significantly decreased during a finite time interval after exposure to 
BEV. We would also predict that as treatment fails, this ratio will once again increase 
towards lactate production and believe that the extent to which the ratio trends towards 
“normal” (i.e., that seen in normal tissue) would correlate with outcome (i.e., it will be a 
reliable gauge of treatment response).  
Ultimately, one could envision such an approach leading to a therapeutic strategy based on 
physiology rather than genetics. Thus, while it is well known that cancer tissues have a high 
rate of GLY, it remains unclear whether lowering the amount of GLY relative to OXPHOS 
would correlate with decreased aggressiveness or whether if the relative amounts were 
lowered to “normal”, growth would “stall”. We believe this ratio (which can be 
mathematically expressed as Cancer aggressiveness =
1
/
k  *
bicarbonate lactate
 ) will be a 
highly sensitive and rapid readout from which one can repeatedly assess both aggressiveness 
and treatment effect. In effect therefore, the opportunity is to use this ratio in a way that 
other physicians may use blood pressure to gauge cardiovascular health.  
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